Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300882 · ClinicalTrials.gov registry record
PREDICT Cytomegalovirus (CMV)
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 84
- Enrollment target
NCT03300882 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 84 participants.
The verdict
NCT03300882 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
The overall objective of this study is to establish a personalized test to measure individualized cytomegalovirus (CMV) specific immunity in lung transplant recipients in an effort to guide antiviral prophylaxis duration in clinical practice. Targeted participants are those: * enrolled in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who * are CMV recipient positive by serology as determined using methods in accordance with current local organ procurement organization policies.
Interventions
- OTHER Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2019-11-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03300882
The ClinicalTrials.gov registry entry for NCT03300882 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Procedure is the first listed.
NCT03300882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03300882 about?
NCT03300882 is a clinical study titled "PREDICT Cytomegalovirus (CMV)". The overall objective of this study is to establish a personalized test to measure individualized cytomegalovirus (CMV) specific immunity in lung transplant recipients in an effort to guide antiviral prophylaxis duration in clinical practice. Targeted participants are those: * enrolled in clinical...
What is the current status of trial NCT03300882?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2017-10-31. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT03300882?
The interventions under investigation include: Procedure (OTHER).
Who is sponsoring clinical trial NCT03300882?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.